{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011069","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.210222+00:00","generated_at":"2026-05-21T05:46:42.133698+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biofrontera Q1 2025 revenue $8.6M (+9% YoY); net loss narrows to $4.2M","bullets":["Total revenues $8.6M, +8.7% YoY; net loss $4.2M ($0.47 per share) vs $10.4M ($2.88) prior year.","Cash and equivalents $1.8M at March 31, 2025, down from $5.9M at Dec 31, 2024.","Phase 3 trial for Ameluz in actinic keratoses on extremities, neck and trunk enrolled final patient; Phase 3 sBCC study completed 1-year follow-up.","Phase 2b study for Ameluz in moderate to severe acne vulgaris completed patient enrollment.","Patent approval extended Ameluz protection to December 2043 for revised formulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011069","json":"https://secwatch.observer/filing/0001641172-25-011069.json","markdown":"https://secwatch.observer/filing/0001641172-25-011069.md","text":"https://secwatch.observer/filing/0001641172-25-011069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000164117225011069/0001641172-25-011069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000164117225011069/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:46:42.133698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}